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ABSTRACT
INTRODUCTION Research has shown that financing drug therapy 
increases smoking abstinence rates, although most of these 
studies have been carried out in the private healthcare setting. 
The aim of this work is to assess the effect of subsidized 
pharmacological treatment on smoking cessation rates by the 
Spanish public healthcare system.
METHODS A pragmatic, randomized, clinical trial was performed 
by clusters. Randomization unit was the primary healthcare 
center and the analysis unit was the patient. Smokers 
consuming ≥10 cigarettes/day were randomly assigned to an 
intervention group that received financed pharmacological 
treatment or to a control group that followed usual care. The 
main outcome was self-reported or CO-confirmed continuous 
abstinence at 12 months. The main outcome, continuous 
abstinence rates (%), were compared between groups at 12 
months post-intervention. A model was adjusted using mixed-
effect logistic regression.
RESULTS A total of 1154 patients were included from 23 
healthcare centers. In the intention-to-treat analysis, self-
reported abstinence after 12 months in the control and 
intervention groups, respectively, was 9.6% (37/387) and 
15.4% (118/767) (gender-adjusted OR=1.75; 95% CI: 1.1–
2.8); for CO-confirmed abstinence the corresponding values 
were 3.1% (12/387) and 6.4% (49/767) (gender-adjusted 
OR=1.72; 95% CI: 0.7–4.0). Pharmacological treatment use was 
35.1% (136/387) in the control group, and 58.3% (447/767) 
in the intervention group (adjusted OR=4.25; 95% CI: 1.8–9.9)
CONCLUSIONS Subsidizing pharmacological treatment for smoking 
cessation increases self-reported or CO-confirmed abstinence 
rates under realistic conditions in the primary care setting of 
the Spanish public health system.
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INTRODUCTION
An array of interventions have been shown to be 
both efficacious and cost-effective in helping patients 
quit smoking1. Among these are pharmacological 
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treatments, which show a greater than twofold 
increase in the rate of successful cessation1,2.
Clinical practice guidelines recommend adding 
drug therapy to behavioral treatment of smokers 
attempting to quit, with some exceptions1. However, in 
the primary care setting, these types of interventions 
are uncommon, non-standardized3–5, and rarely 
include pharmacological treatment5–7. The treatment 
cost and lack of financing by the public healthcare 
system may be one of the reasons for not being more 
widely used8.
The Cochrane Systematic Reviews9 have assessed 
the effectiveness of funding treatments for smoking 
cessation and concluded that full financing of the 
treatment increases abstinence rates and number of 
attempts, almost doubling the rate of use of nicotine 
replacement therapy (NRT) and tripling that of 
Bupropion. Studies that compared the effect of 
funding the cessation obtained a combined relative 
risk for abstinence for at least 6 months of 1.77 (95% 
CI: 1.37–2.28) and 1.27 (95% CI: 1.02–1.59) in the 
case of full and partial funding, respectively.
A study has been published, using ecological 
momentary assessment methods with an interrupted 
time-lapse analysis, of fully financed smoking 
cessation treatments during 2011 by the Netherlands 
government, including drug therapy. In the studied 
period, primary care doctors prescribed more 
therapeutic drugs and smoking prevalence decreased. 
However, once the pharmacological coverage ceased, 
drug prescriptions decreased and smoking prevalence 
rebounded10. The number of smokers attended to by 
the Dutch telephone help-line for smoking cessation 
went from 848 in 2010 to 9091 in 2011 and dropped 
drastically after the funding ended in 2012 (only 151 
in the first 18 weeks)11.
Pharmacological treatment is considered a 
complementary measure to others that decrease 
smoking addiction prevalence11,12 such as increasing 
tobacco taxes or smoke-free areas13. It is especially 
relevant for highly-dependent and low-income 
smokers, who show greater difficulties to quit 
smoking14–16, and has been associated with a decrease 
in hospital admissions due to cardiovascular disease17.
Most relevant studies have been conducted in the 
private healthcare setting, mainly in the USA9. In the 
public healthcare setting, two main studies have been 
performed, a pilot study with short-term outcomes in 
the United Kingdom primary care system18, whose 
National Health System is similar to the Spanish 
one, and a subsequent study in the Canadian Health 
System, which is public with private provision19. 
Primary care in Spain is organized in healthcare 
centers (HCCs), with public provision, where both 
health and non-health professionals work together 
to attend to users in their health area. Care for 
smokers, which is included in the services provided 
by health professionals as paid work, encompasses 
counselling, behavioral interventions, and suggesting 
pharmacological treatment at the patient’s expense. 
The aim of this study was to know whether funding 
pharmacological treatment for smoking cessation in 
primary care increases abstinence rates under realistic 
conditions.
METHODS
A pragmatic, controlled, clinical trial was performed 
with paralleled groups randomized by clusters. The 
trial was approved by the Ethics Committee for 
Clinical Research of Hospital Doce de Octubre de 
Madrid. 
Ninety-six HCCs in the Health System of the 
Community of Madrid were asked to participate. The 
HCCs were selected by convenience among those 
interested in participating. The inclusion criterion 
for HCCs was: having at least one doctor interested 
in participating in the trial. Twenty-nine HCCs, which 
provide health care to a population of 925000 citizens, 
aged >14 years, accepted to participate.
The inclusion criteria for the patients were: aged 
>18 years who attended the healthcare center for any 
reason between June and December 2009, smoking 
≥10 cigarettes/day, at any stage of the smoking 
cessation process, attended by a general practitioner 
or nurse that addressed smoking cessation following 
usual clinical practice, and a signed informed consent. 
Pregnant and nursing women were excluded1.
Sample size and sampling
Sample size was calculated considering that 8% of 
smokers treated with the intervention would stay 
abstinent after 1 year20, a clinical significance of 75% 
improvement post-intervention, a type I error of 5%, 
and a power of 80%. The obtained sample size was 
459 patients. After controlling for the design effect, 
estimating an average cluster size of 25 patients and 
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intraclass correlation coefficient of 0.02, and adding 
20% of losses to follow-up, a total of 1632 smokers 
were included, with 816 per group. Allocation was 
performed by clusters, the primary HCC being the 
randomization unit. The 29 HCCs were assigned to the 
intervention or the control group following a simple, 
computer-generated random sequence (EPIDAT 3.1 
software). Randomization was performed centrally by 
a researcher not involved in the study, and who was 
blind to the identity of the HCCs.
Intervention
Behavioral treatment and recommendation for using 
pharmacological treatment were administered to both 
groups, in accordance with standard health services 
offered in primary care. In order to homogenize 
criteria and guarantee quality care for the smoker, 
general practitioners and nurses from the included 
healthcare centers received specific training as 
proposed by Olano et al.21. 
Patients in the intervention group received first-
line pharmacological treatment free-of-charge. The 
active ingredient (nicotine, Varenicline, or Bupropion) 
was chosen by the health professional in accordance 
with the patient’s preferences. Treatment doses were 
standard: NRT according to the number of cigarettes 
smoked, Bupropion at 150–300 mg/d and Varenicline 
at 1–2 mg/d. Treatment combinations were allowed 
at the discretion of the physician, such as NRT 
patch-plus or Bupropion and nicotine gum. The 
proposed standard duration was 8 weeks for NRT and 
Bupropion, and 12 weeks for Varenicline. Medication 
was distributed to the participating HCCs from the 
pharmacy services of the public health system. In the 
first visit, patients were given treatment for 2 weeks. 
At subsequent visits, they were given treatment for 
1 month.    
Patients in the control group were prescribed the 
treatment at the consultation and had to purchase it.
As it was a pragmatic trial, no visits other than 
standard practice were offered. Follow-up visits were 
left to the discretion of the professionals, according 
to their usual practice. The patients were followed 
for 12 months from the quit date, until December 
2010.
Patients who did not intend to quit smoking 
were offered advice, but they were not given an 
appointment in either group.
Variables
Main outcome variables were: continuous abstinence 
according to the criterion by Russel22 and biochemically 
validated abstinence through CO-oximetry. 
Appointments were given to patients that confirmed 
abstinence for validation via a CO-oximetry test, by 
Smokerlyzer Pico cooximeter, with a cut-off point of 
<7 ppm. 
Secondary outcome variables were: use of 
pharmacological treatment and type of therapeutic 
drug (nicotine, Bupropion, and Varenicline). Data 
were collected at 12 months ±4 weeks from the 
quit date from electronic clinical records or, when 
information was not available, abstinence was 
confirmed via telephone call. 
Baseline variables were: age, gender, educational 
level, socioeconomic level, daily cigarette consumption, 
pack-years, score in the Fagerström Test for Nicotine 
Dependence (FTND), previous attempts to quit, stage 
of change, and previous use of drug therapy.
Statistical analysis
A descriptive analysis, of frequencies for qualitative 
variables and mean with standard deviation (SD) for 
quantitative variables, was performed. The groups 
were compared at the baseline in terms of outcome 
variables, descriptive variables, and prognosis 
factors. A bivariate analysis to compare variables was 
performed, using a chi-squared test and a Student’s 
t-test, in the case of dichotomous and continuous 
variables, respectively.
Main outcome was percentages of self-reported or 
CO-oximetry validated abstinence compared between 
the intervention and control groups, with 95% 
confidence intervals (95% CI). Intention-to-treat data 
analysis was performed at 12 months. Missing values 
for the main outcome variable were added using the 
‘basal observation carried forward’ method. For the 
secondary aim analysis, effectiveness was evaluated 
by comparing the differences in the percentages of 
pharmacological treatment use at 12 months between 
both groups, and corresponding 95% CI.  
A multilevel, logistic regression model was built 
at 12 months, where the dependent variable was 
self-reported (Yes/No) or CO-oximetry validated 
abstinence (Yes/No) or pharmacological treatment 
use (Yes/No), respectively, and the independent 
variable was the patient’s allocation group. Clinically 
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significant variables were also tested as covariates, 
taking into consideration sampling by clusters.
Statistical SPSS 21 and STATA 14 software were 
employed for all calculations.
RESULTS
A total of 255 health professionals from 23 healthcare 
centers participated in the trial and 1154 patients 
were included, 387 in the control group and 767 in 
the intervention group. Figure 1 shows the flow chart 
of participants throughout the trial. No differences 
were found in terms of number of consultations, rural 
or urban setting, and sociocultural level between the 
6 non-participating centers (5 in the control arm and 
1 in the intervention arm) and those participating in 
the study. 
Baseline data were similar for both groups except 
that the intervention group comprised a larger 
percentage of men, smoked more cigarettes per day, 
and showed higher scores in the FTND (Table 1). 
Additionally, the rate of patients at the preparation and 
action stages of the cessation process was significantly 
higher in the intervention group. 
Losses to follow-up were similar in both groups, 
with values of 7% (n=54) and 8.5% (n=32) in 
the intervention and control groups, respectively 
(p=0.38). Compared to the intervention group, 
subjects lost to follow-up in the control group had a 
higher income level (70% vs 30%, p=0.045) and used 
less drugs (15% vs 85%, p=0.007).
With regard to the main outcome, the patients who 
self-reported having quit smoking at the 12 months 
follow-up were 118 (15.4%) and 37 (9.6%) in the 
intervention and control groups, respectively. Of 
these, 57 (48%) from the intervention group and 
14 (38%) from the control group attended the CO-
oximetry validation appointment, and abstinence was 
confirmed in the case of 49 patients (6.4%) from 
the funded-treatment group and 12 (3.1%) from the 
non-funded (Table 2).  Abstinence rates were higher 
for subjects with higher income level for both arms 
(Table 3). The difference in abstinence rates and use 
of pharmacological treatment between high-income 
(>€26000/year) and low-income subjects (<€26000/
year) was reduced after financing of the treatment 
(Table 3). Having used therapeutic drugs in previous 
attempts increased the success of quitting in the 
financed-treatment group (Table 4).
For the secondary outcome use of pharmacological 
treatment was significantly greater in the case of 
the subsidized arm (58.3%) compared to the non-
financed (35.1%) (Table 2). 
Four per cent of the abstinence variability per year 
is explained by clusters (HCCs). The MOR (median 
odds ratio) between centers was 1.4, which can be 
interpreted as the increase in risk (median) that an 
individual would have if they were moved from one 
center to another with a higher risk.
Figure 1. Flow chart of participants
Healthcare centers randomly assigned 
(29 centers, 371 GPs, 350 nurses)
Usual care arm
(15 centers: 43 GPs and 18 nurses. 
Recruited patients: 10 centers)
(n=387 patients; median per center 
38.7; range 7–87)
Patients analyzed for the primary 
outcome (n=387)
Participants lost to follow-up (n=32) 
Unknown
Intervention arm 
(14 centers: 125 GPs and 69 nurses. 
Recruited patients: 13 centers)
(n=767 patients; median per center 
59.0; range 19–140)
Patients analyzed for the primary 
outcome (n=767)
Participants lost to follow-up (n=53) 




30 patients not meeting criteria
170 patients without consent
11 recruitments out of period
(67 centers excluded – declined to 
participate)
Excluded patients: n=274
35 patients not meeting criteria
239 patients without consent
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All variables that showed basal differences and 
those that could impact the outcome from a clinical 
point of view were included in the multilevel model. 
After removing all non-significant variables, gender 
remained as the only adjustment factor. Self-
reported continuous abstinence, adjusted by gender, 
was significantly greater in the intervention group 
(OR=1.75; 95% CI: 1.1–2.8); validated abstinence 
by CO-oximetry was also higher (OR=1.72; 95% CI: 
0.74–4.0). Abstinence rates in both the intervention 
and control arms increased using NRT (OR=2.0; 95% 








Age (years), mean (SD) 46.04 (11.78) 46.6 (12.06) 45.8 (11.64) 0.268
Gender, n (%)
Male 593 (51.4) 174 (45.0) 419 (54.7) 0.001
Female 560 (48.6) 213 (55.0) 347 (45.3)
Educational level, n (%)
No studies 25 (2.5) 4 (1.4) 20 (2.9) 0.184
Primary education 326 (32.9) 102 (34.7) 223 (32.4)
Secondary education 387 (39.0) 105 (35.7) 279 (40.5)
University 254 (25.6) 83 (28.2) 167 (24.2)
Annual income level, n (%)
<€26000 669 (69.7) 191 (65.6) 478 (71.4) 0.072
≥€26000 291 (30.3) 100 (34.4) 191 (28.6)
Cigarettes/day, mean (SD) 22.0 (9.5) 20.6 (8.6) 22.6 (9.9) 0.012
Years smoking, mean (SD) 26.5 (11.9) 27.1 (12.4) 26.1 (11.6) 0.190
Pack-years, mean (SD) 29.6 (19.9) 28.6 (18.7) 30.2 (20.5) 0.220
Number of previous attempts, mean (SD) 2.3 (3.1) 2.2 (2.5) 2.4 (3.5) 0.159
FTND, mean (SD)* 5.4 (2.2) 5.2 (2.1) 5.5 (2.3) 0.035
Previous drug therapy, n (%) 178 (25.5) 68 (26.6) 110 (24.9) 0.625
Stage of change, n (%)
Pre-contemplation 252 (22.2) 103 (26.6) 150 (19.6) <0.01
Contemplation 239 (21.1) 105 (27.1) 134 (17.5) <0.01
Preparation 385 (34.0) 113 (29.2) 272 (35.5) 0.03
Action 253 (22.3) 58 (15.0) 196 (25.5) <0.01
Table 1. Baseline characteristics of participants by group






n (%) n (%) OR ( 95% CI) OR raw ( 95% CI)a p AORb ( 95% CI) p
Self-reported continuous abstinence 37 (9.6) 118 (15.4) 5.8 (1.9–9.7) 1.84 (1.1–3.0) 0.01 1.75 (1.1–2.8) 0.02
CO-validated continuous abstinence 12 (3.1) 49 (6.4) 3.3 (0.8–5.7) 1.77 (0.8–4.1) 0.17 1.72 (0.7–4.0) 0.20
Pharmacological treatment use 136 (35.1)c 447 (58.3)d 23.1 (17.2–29.0) 4.52 (2.0–10.0) 0.00 4.25 (1.8–9.9) 0.00
NRT 46 (11.9) 131 (17.1) 5.2 (1.0–9.4) 1.80 (1.0–3.3) 0.05 1.77 (1.0–3.2) 0.06
Bupropion 45 (11.6) 135 (17.6) 6.0 (1.8–10.2) 1.58 (0.8–3.1) 0.19 1.49 (0.7–3.0) 0.83
Varenicline 49 (12.7) 199 (25.9) 13.2 (8.7–17.8) 3.40 (1.8–6.4) 0.00 3.41 (1.8–6.5) 0.00
Table 2. Outcomes of continuous abstinence (self-reported or CO-validated) and use of pharmacological 
treatment, from mixed-effect logistic regression analysis 
a Mixed-effect logistic regression, b AOR: adjusted odds ratio by gender, c 4 participants used Bupropion+NRT, d 10 used Bupropion+NRT; 7 Varenicline+NRT; 1 
Bupropion+Varenicline.
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and Varenicline (OR=3.0; 95% CI: 2.1–4.3) (Table 
5). In the case of NRT, the impact was significantly 
greater in men (2.75; 95% CI: 1.6–4.6) than in women 
(1.2; 95% CI: 0.6–2.4). 
Success in quitting smoking was greater for men 
(OR=1.5; 95% CI: 1.1–2.2) and subjects with high-
income level (OR=1.6; 95% CI: 1.1–2.3).
DISCUSSION
Financing pharmacological treatment for smoking 
cessation in this trial significantly increased self-
reported abstinence rates at the 12 months follow-
up, and validated abstinence by CO-oximetry. The 
use of drug therapy also increased significantly, 
especially with nicotine and Varenicline. Additionally, 
the number of patients willing to attempt cessation 
in the intervention arm was much higher (Table 1). 
A design by clusters was chosen considering the 
organization of the Spanish healthcare system and 
high risk of cross-contamination between participants. 
The trial was conducted in real-world conditions 
within the public health system context, with a high 
number of daily consultations, which forced patient 
recruitment to take place after randomizing the 
centers. Baseline differences shown in Table 1 appear 
to already indicate an intervention impact prior to 
its initiation. At the initial visit, patients were aware 
of the possibility of financing the treatment, which 
probably encouraged many participants to escape 
the first stages of the process and directly proceed to 
attempt to quit. 
After refining the multilevel model, where gender 
remained as the only adjustment factor, differences 
in biochemically-validated abstinence lacked 
significance, which is probably due to the low ratio 
of participants who attended biochemical validation 
Group  Abstinence Pharmacological treatment use
% (n) OR ( 95% CI) % (n) OR ( 95% CI)
Usual practice No previous use of drugs 13.3 (25) 40.4 (76)
Previous use of drugs 10.3 (7) 1.2 (0.7–1.9) 51.5 (35) 2.3 (1.6–3.3)
Financed treatment No previous use of drugs 15.1 (50) 60.5 (201)
Previous use of drugs 21.8 (24) 2.4 (1.0–6.0) 80.0 (88) 3.8 (1.9–7.3)
Total Financed treatment 16.7 (74) 65.4 (289)
Non-financed treatment 12.5 (32) 1.4 (0.9–2.2) 43.4 (111) 2.5 (1.8–3.4)












Continuous abstinence 38 (21.5) 117 (12) 42 (23.3) 113 (11.6) 63 (25.4) 92 (10.2)
OR (95% CI) 2.0 (1.3–3.0) 2.3 (1.6–3.4) 3.0 (2.1–4.3)
Table 4. Outcomes of abstinence rates and use of pharmacological treatment by previous use of 
pharmacological treatment
Table 5. Outcomes of continuous abstinence (self-reported) with NRT, Bupropion and Varenicline 
Group  Abstinence Pharmacological treatment use
% (n) OR ( 95% CI) % (n) OR ( 95% CI)
Control group <€26000 7.9 (15) 29.3 (56)
≥€26000 15.0 (15) 1.81 (1.0–3.3) 47.0 (47) 2.9 (2.0–4.2)
Intervention group <€26000 13.4 (64) 54.8 (262)
≥€26000 19.4 (37) 1.4 (0.7–2.6) 62.3 (119) 1.9 (1.1–3.0)
Total Usual practice 10.3 (30) 35.4 (103)
Financed treatment 15.1 (101) 1.5 (1.0–2.4) 57.0 (381) 2.4 (1.8–3.2)
Table 3. Outcomes of abstinence rates and use of pharmacological treatment by annual income level
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and the lack of power resulting from not reaching the 
calculated sample size.
This outcome is similar to other studies. Kaper et 
al.23 reported a biochemically-validated abstinence 
rate of 5.5% in the intervention group and 2.8% in the 
control group (OR=2.3; 95% CI: 1.2–4.1), and a self-
reported abstinence of 7.8% and 5.5%, (OR=1.5; 95% 
CI: 0.9–2.4), respectively. Use of drug therapy was 
10.8% in the financed group and 4.1% in the control 
(OR=2.9; 95% CI: 1.8–4.7).
Selby et al.19 conducted a pragmatic study with 
similar results after 6 months, and the Cochrane 
Review relative risk was within the same range9. A 
study by Twardella et al.24 with a similar design by 
clusters found a continuous abstinence rate of 9% 
for a group provided with training and financing 
compared to 1% success in a group treated following 
usual clinical practice.
Financing pharmacological treatment can be an 
important factor to help vulnerable populations quit 
smoking14–16. The higher the income, the greater the 
probability to cease smoking and the lower the tobacco 
consumption prevalence25. In this study, patients 
with a higher income level in both arms were more 
successful in quitting. However, in the intervention 
group, differences in drug use and abstinence rates 
were smaller between subjects with high- and low-
income levels, which indicate a tendency to balance 
pharmacological treatment use as a result of funding 
it (Table 3). High income level was considered to be 
greater than €26000/year, the equivalent of more 
than 3 times the minimum interprofessional salary 
in the study period. The number of attempts to quit 
is considered a criterion of dependence: the greater 
the number of attempts, the greater the nicotine 
addiction. According to some studies23, smokers who 
have ever used drug therapy have more possibilities to 
re-use it if subsidized. In our study, smokers that had 
previously used drug therapy, used it more frequently, 
and also had greater chance to quit smoking (Table 
4).
A study26 in the Netherlands reported the real-
world experience of financing drug therapy in 2011 
and compared the results with those from a 5% 
increase in tobacco prices at that time. Treatment 
funding yielded better health outcomes, although at 
a higher cost, but none of the mentioned strategies 
reduced the gap between social groups.
In most studies on this topic, NRT and Bupropion 
have been used. The latest also include Varenicline. 
All are considered first-line therapies in smoking 
cessation1,2. According to the latest reviews Varenicline 
is more effective than Bupropion and single-form NRT 
but not of the combination NRT2,27. In this trial, all drugs 
have shown their effectiveness in stopping smoking. 
The use of NRT and Bupropion doubles the chances of 
quitting smoking and Varenicline triples them. They are 
figures similar to those found in the literature1. Each 
one of the three drugs was more used when the patient 
did not have to pay for it. Therefore, NRT, Bupropion 
and Varenicline would be candidates to be subsidized. 
In Spain, the main experience of financing treatment 
took place in the Autonomous Community of Navarra, 
between 2003 and 2012. After 5 years, since December 
2017, it is also subsidized in primary healthcare centers 
(HCCs), in the context of support and follow-up. In 
Madrid, a pilot funding experience was made in certain 
patients with chronic conditions for a few months in 
2011. Treatments for other chronic conditions such as 
hypertension, diabetes, COPD, and alcohol abuse, have 
always been subsidized.
Limitations and strengths
There are some limitations to this study. The funding 
requested for the conduct of the study was estimated 
considering that 15–20% of smokers would make 
an attempt to quit but the rate was much higher in 
both groups, likely due to the real offer to actually 
quit smoking28, together with a possible Hawthorne 
effect. Thus, the budget assigned to the project for 
funding pharmacological treatment ran out before 
completing the required sample size, since up 
to 58% of participants in the intervention group 
used pharmacological treatment. At the same time, 
the control group recruited less participants than 
expected, all of which resulted in a lack of power for 
some outcomes. This is probably related to the real-
life impact of the intervention. Primary healthcare 
interventions are scarce3–8. The possibility of giving 
a treatment leads to an increased intervention by the 
practitioner, so many participants decided to make an 
attempt. In contrast, in the control group, recruitment 
was slower in the same period since interventions are 
rarer.
It is not to be expected that financing a drug will 
increase its efficacy, but that the number of attempts 
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to quit smoking and the use of pharmacological 
support will be increased. Professionals attract more 
patients because they offer more financed treatment 
and patients decide to make an attempt as they know 
that treatment will be funded. The main reason for the 
difference in the distribution of the stages of change 
is most likely the treatment offer itself, which is the 
subject of the study, although selection bias cannot 
be discarded. This is why the multilevel analysis was 
not adjusted for the stages of change.
The calculation of the number of patients who 
would attempt to stop smoking was done according 
to the theoretical framework of the stages of 
change. Some authors suggest a different theoretical 
framework, called the ‘Catastrophic theory’29, which 
considers motivation as a dynamic, fluctuating process 
where diverse stimuli can trigger attempts to quit. 
Even small triggers can lead to sudden ‘catastrophic’ 
changes. One of those stimuli that could trigger quit 
attempts could be the immediate offer of a funded 
treatment. In a clinical trial by Jardin et al.30, both 
motivated and unmotivated patients were given 
free NRT and referred to a telephone help-line for 
cessation, and similar abstinence rates were observed. 
Funding the treatment can be one trigger stimulus 
for less motivated smokers to attempt cessation. 
This may explain differences between groups across 
the different stages of the change process, and 
consequently in the number of quit attempts. 
As is the case for studies by clusters, another 
possible limitation is the selection and attrition biases. 
The control arm recruited fewer patients, possibly due 
to the lack of involvement of health professionals 
not assigned to the intervention arm, and a higher 
number of centers in the control arm did not recruit 
any patients. Another bias can be the temporariness 
of the funding assigned to the project, of which 
health professionals were aware of and which may 
have influenced their decision to recruit more patients 
willing to quit smoking for the intervention group28. 
Identification of patients prior to randomization or 
blinding of professionals in charge or recruitment was 
not possible. 
Another limitation is the irregular distribution 
of HCCs (cluster) in the two arms. The number 
of professionals in the control group (doctors and 
nurses) was much lower than in the intervention 
group (Figure 1), which may have influenced the 
lower uptake of patients in the control group. Despite 
this, the average uptake per center was not much 
lower in the control HCCs. 
Among the strengths of this study is its pragmatic 
design31 for assessing the effect of treatment funding 
under real-life conditions. Recruitment, training of 
health professionals21, information and assistance for 
patients, and characteristics of healthcare centers and 
professionals were identical in both groups. Criteria 
for inclusion, flexibility to apply the intervention, 
comparison with usual practice, absence of formal, 
controlled follow-up visit, and the intention-to-treat 
analysis were also part of our pragmatic design. 
Smokers were treated by their assigned health 
professionals at usual consultations, without further 
limitations. Situations where pharmacological 
treatment is not indicated was the only exclusion 
criterion1. We consider that these results can be 
applied to real-world primary care consultations in the 
Spanish setting. Drug financing has not been modified 
in our environment since the trial was conducted.
An intervention on smoking dependence does 
not consist of a mere pharmacological prescription. 
Treatment mainly consists of behavioral counselling. 
However, use of drug therapy is an important 
facilitator, especially in the case of underprivileged 
patients, as is the case for the highly-dependent or 
those from a low socioeconomic level. Hence, funding 
this treatment in a manner similar to other treatments 
already financed by the public system is a key factor.
CONCLUSIONS
Financing pharmacological treatment of smoking 
addiction by the public health system increases 
abstinence rates and offers the opportunity to improve 
interventions for tobacco consumption in primary 
care, with increased number of attempts to quit and 
use of therapeutic drugs.
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